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Biological Pacemakers
Are We at the Dawn
of a New Treatment Era?*
Matteo Vatta, PHD,† Douglas P. Zipes, MD‡
Indianapolis, Indiana
In this issue of the Journal, Boink et al. (1) reported the
study of biological pacemaker function in mongrel dogs that
underwent radiofrequency ablation of the atrioventricular
node and were then treated with gene transfer using the
hyperpolarization-activated cyclic nucleotide–gated current
channel 2 (HCN2) construct, the skeletal muscle sodium
channel (SkM1) construct, or the dual (HCN2/SkM1) con-
struct injected into the left bundle branch (LBB) or the left
See page 1192
ventricular (LV) subepicardium. The researchers coex-
pressed SkM1 with HCN2 on the basis of the hypothesis
that when HCN2 generated the inward current that would
drive the membrane toward threshold, SkM1 would create
greater availability of sodium channels during diastole be-
cause of a more favorable inactivation curve than the cardiac
sodium channel, leading to a more negative threshold
potential, improved pacemaker stability, and increased beat-
ing rates. Indeed, that is what they found. Five to 7 days
after injection, upon stable maximal expression of the
HCN2/SkM1 construct, LBB-injected dogs demonstrated
higher heart rates (80 to 130 beats/min) and better modu-
lation of pacemaker function during circadian rhythm or
epinephrine infusion and did not require electronic pacing
backup, compared with LV injected dogs and dogs with
LBB injections expressing SkM1 or HCN2 alone (1). The
esearchers concluded that this model is more biologically
uitable for pacing than other constructs reported, findings
hey attribute to the more negative action potential thresh-
ld and injection into the LBB. The actual contribution of
ach compound was not investigated, and likely some cells
xpressed HCN2 and others SkM1 in varying relationships
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ected with one gene or the other. Overall, the functional
ombination capitalizing on their different and complimen-
ary mechanisms of action was successful, maybe from the
veraging effects brought about by the cable properties of a
unctional cardiac syncytium (2,3).
The current report suggested that the expression of
CN2, rather than other isoforms such HCN4, along with
kM1 in the canine LBB, was sufficient to provide an
mproved automaticity and autonomic responsiveness sim-
lar to the highly expressing HCN4 in sinus node pacemaker
ells (1). Although cardiac function in LBB-injected dogs
ppeared to be grossly improved, it remains unclear how
xogenous HCN2/SkM1 expression in LBB-injected cells
s sufficient to functionally compensate for the difference in
natomic structure and protein expression of LBB cells
ompared with sinus node pacemaker cardiomyocytes. In
ddition, further investigation is needed to elucidate
hether overexpression of HCN2 in LBB cells leads to the
xclusive assembly of functional homotetrameric HCN2
hannels or the current observations derived from altered
ubunit stoichiometry of the existing HCN channels, sup-
orting alternative heterotetrameric HCN channels with
ntermediate or different activation time constants, steady-
tate voltage dependence, and cAMP-dependent modula-
ion leading to If channel heterogeneity.
These excellent scientists are to be congratulated on a
creative hypothesis established by careful experimentation.
Although it appears that the reported construct is better
than previous attempts, it is also true that the normally
functioning sinus node is a tough act to follow, as is a
modern electronic pacemaker, and we need to consider
whether the ultimate goal to replace a malfunctioning sinus
node with a biologically active pacemaker to avoid the
problems associated with electronic pacemakers, particularly
leads, is achievable. So, let’s put on our clinician hat and
evaluate the findings in that light.
First, will the construct work in the atrium? The sinus
node contains specialized cardiomyocytes, the pacemaker
cells, with a resting potential of approximately 70 mV,
that undergo spontaneous depolarization and are character-
ized by low conductance compared with the adjacent and
fast-conducting atrial cardiomyocytes (4). The characteristic
conductance of the sinus node allows directional propaga-
tion of the depolarization wave and prevents the overhyper-
polarization from neighboring atrial cardiomyocytes. This
low conductance is granted by the combination between the
peculiar anatomic structure and cell composition of the
sinus node, as well as the exclusive ion channels, pumps, and
gap junction protein milieu of the pacemaker cells, which
dramatically diverge from the atrial and ventricular car-
diomyocytes (5– 8). Granted that the combination con-
struct was not very effective injected into the LV myo-
cardium, the issue now is how well it will work injected
into atrial myocardium. Will the unique atrial anatomy
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gize functionally?
A second issue is durability and longevity. The research-
ers were appropriately cautious and stated that biological
pacing is being explored as a possible adjunct or replacement
for electronic pacing but that a good deal remains to be done
before clinical testing is in order. We would agree with that
caveat. Long-term expression of a HCN2/SkM1 construct
will require alternative vectors that can integrate into the
genome of the transfected cardiomyocytes, thus offering
stable and long-lasting expression of the exogenous gene
products (9,10). The researchers suggested that because of
myocardial cell targeting as well as the DNA size packaging
capability of the current available systems, lentiviral vectors
may be more suitable to translate their finding into clinical
application. However, lentiviral vectors may not be useful
for all biological applications because DNA inserts 6 kb
may dramatically decrease the viral titers due to reduced
packaging efficiency, thus hampering the application range
of this type of therapy (11). They also offered that overex-
pressing human mesenchymal stem cells may be a reason-
able approach. However, given a projected 8-year survival of
an electronic pacemaker, there is a challenge ahead to create
a biological substitute capable of initiating roughly 300
million beats without fail and on time.
A third issue is to demonstrate that whichever construct
is used, it is not arrhythmogenic and that it responds as a
normal pacemaker to autonomic influences (partially shown
here), circulating modulators, as well as to ectopic beats,
with capture and resetting, to avoid the impact of competing
pacemakers and potential arrhythmogenicity. Injection into
the LBB in the human ventricle may be quite challenging
but may be preferable to right ventricular apical pacing,
especially for patients with LBB block.
Finally, if the intent of the researchers is to provide a
ventricular pacemaker, rather than a substitute for the sinus
node, then the issues of ventricular capture and resetting
noted above become even more important. In addition, such
a pacing application would function as a VVI pacemaker,
generally less favorable than DDD pacing.
In summary, despite the many points that remain to be
elucidated and the technical limitations to be addressed, Nthe effort of Boink et al. (1) along with other research
groups to establish a biological alternative to electrical
pacemakers is extremely significant for the possible clin-
ical applications and the improvement in patient man-
agement. None of the clinical problems detract at all from
the science but do demonstrate that we will have job
security for quite some time to come.
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